July 19, 2010

Link suggested between scleroderma and cancer in certain patients

Patients with a certain type of scleroderma may get cancer and scleroderma simultaneously, Johns Hopkins researchers have found, suggesting that in some diseases, autoimmunity and cancer may be linked.

These findings could lead researchers closer to discovering what causes scleroderma, an incurable autoimmune disease that causes scar tissue to develop in the skin and in major organ systems, and to pinning down why some with scleroderma appear to be at increased risk of cancer. The insights add to the growing body of evidence linking some autoimmune disorders with cancer.

“Our research adds more to the discussion about whether cancer and autoimmune diseases are related and whether cancer may be a trigger for scleroderma,” said Ami A. Shah, an assistant professor of medicine in the Division of Rheumatology at the Johns Hopkins University School of Medicine and the study’s lead author.

The small study, which appears online in the journal Arthritis & Rheumatism, looked at blood and tumor samples from 23 patients with both scleroderma and cancer who were treated at the Johns Hopkins Scleroderma Center. Ten percent of the patients have cancer as well as the autoimmune disease.

The researchers looked for specific immune markers in each patient, determining which type of antibodies the patients made. Those with antibodies called anti-RNA polymerase I/III had the most closely related onset of cancer and scleroderma, they found. Those patients got both diseases, within two years of one another. Similar results were found in another subset of patients—those who tested positive for none of the known autoimmune antibodies. Researchers suspect that there are immune markers in their blood that have yet to be discovered.

The reasons for the apparent link between scleroderma and cancer are not understood, Shah said, and it is unknown whether cancer could be causing scleroderma, or if scleroderma could be causing cancer.
Most often, Shah said, the patients developed cancer first, and scleroderma soon after. She said that one theory, as yet unproven, is that as the body generates an immune response to fight a tumor, the immune response could trigger the development of scleroderma. It is also possible, she said, that the immune response could successfully defeat a developing tumor but still result in scleroderma. Another possibility could be that organ damage from scleroderma could predispose patients to cancer. Or it could be that the use of immune-suppressing drugs to treat scleroderma could lead to cancer.

She said that some reports in the medical literature have shown that in cases of concurrent cancer and scleroderma, treating the cancer halted the progression of the autoimmune disorder.

Several other autoimmune disorders also appear to have potential links to cancer, Shah said. This research could have implications for those diseases as well.

Many questions remain and more research is needed, said Livia Casciola-Rosen, an associate professor of medicine in the Division of Rheumatology at the Johns Hopkins School of Medicine and one of the study’s principal investigators. “Are particular antibodies in scleroderma associated with increased risk of cancer? Maybe we need to look,” she said. “And if you develop both at the same time, does treatment of one affect the outcome of the other? This research,” she said, “is really just the beginning.”
The study was supported in part by funding from the Scleroderma Research Foundation, Stabler Foundation, Karen Brown Scleroderma Foundation, American College of Rheumatology Research and Education Foundation and National Institutes of Health. Other Johns Hopkins researchers contributing to the study are Antony Rosen, Laura Hummers and Fredrick Wigley.